Standard
New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. / Kjaer, Andreas (Opfinder); Persson, Morten (Opfinder); Ploug, Michael (Opfinder).
Patentnummer: CN104768573. jul. 08, 2015.
Publikation: Patent
Harvard
Kjaer, A, Persson, M & Ploug, M jul.. 08 2015, New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors, Patentnummer CN104768573.
APA
Kjaer, A., Persson, M., & Ploug, M. (2015). New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. (Patentnummer CN104768573).
Vancouver
Kjaer A, Persson M, Ploug M, Opfindere. New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. CN104768573. 2015 jul. 8.
Author
Kjaer, Andreas (Opfinder) ; Persson, Morten (Opfinder) ; Ploug, Michael (Opfinder). / New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. Patentnummer: CN104768573. jul. 08, 2015.
Bibtex
@misc{8f7e108f24f948819f2b98736f69b76d,
title = "New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors",
abstract = "There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.",
author = "Andreas Kjaer and Morten Persson and Michael Ploug",
year = "2015",
month = jul,
day = "8",
language = "English",
type = "Patent",
note = "CN104768573; C07K 16/ 30 A I",
}
RIS
TY - PAT
T1 - New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors
AU - Kjaer, Andreas
AU - Persson, Morten
AU - Ploug, Michael
PY - 2015/7/8
Y1 - 2015/7/8
N2 - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
AB - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
M3 - Patent
M1 - CN104768573
ER -
